Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN-002 for BCC in BCNS
NCT03208296Phase 2Suspended
- Sponsor
- Ascend Biopharmaceuticals Ltd.
- Start
- Dec 2017
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gusacitinib in basal cell carcinoma (BCC), sponsored by Ascend Biopharmaceuticals Ltd.. Started Dec 2017; status: suspended.
02
Drugs
gusacitinib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03208296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208296.